While Amarin (AMRN) is trading lower after Hikma Pharmaceuticals (HKMPF) announced the first FDA approval for a generic Vascepa, there is a low likelihood of an at-risk launch, Roth Capital analyst Yasmeen Rahimi tells investors in a research note. When combined with Amarin’s “position of strength in its expedited appeals argument,” the selloff today presents a buying opportunity, contends the analyst. Rahimi sees a low likelihood of an at-risk launch due to the potential liabilities on an appeal loss as well as the complexity of manufacturing. The analyst keeps a Buy rating on Amarin with a $31 price target. The stock is well off its lows in morning trading but remains down 5c to $7.23.